The Board of Directors of Cereno Scientific announces the proposal of Anders Svensson as a new Board member. Behind the proposal are shareholders representing a majority of the shares and votes in the company. In addition, the Board announces that Board member Gunnar Olsson has resigned his seat on the Board of Directors, but will continue his involvement in the company as a Senior Adviser.
Anders Svensson is a licensed physician, medical doctor and lecturer with over 20 years of experience in academic medicine; his scientific focus is cardiovascular diseases. After a period in academia, Dr. Svensson also held leading positions at AstraZeneca, including VP Clinical for Cardiovascular and Gastrointestinal Development. Subsequently Anders was the Head of Global Clinical Development for Diabetes and Cardiovascular for one of the world’s largest drug companies, F. Hoffmann-LaRoche in Switzerland.
“I am convinced that Anders Svensson, with his broad contact network and extensive experience in drug development after more than 40 years in the industry, will be a major asset to Cereno in the continued work of the Board,” says Catharina Bäärnhielm, Chairman of the Board of Cereno Scientific.
The decision to choose Anders Svensson as a new Board member will be taken at an extraordinary general shareholders’ meeting. The notice to attend the meeting will be published shortly.
“I would like to take this opportunity to thank Gunnar Olsson on behalf of the Board for his active involvement since 2016 as a Board member in the company. We are very pleased that he will continue to support the company’s future as a Senior Adviser with his extensive experience and skills,” says Catharina Bäärnhielm.
About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body’s own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific’s drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca’s BioVentureHub and is supported by GU Ventures. Cereno Scientific’s B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.
This information is such that Cereno Scientific AB is required to make public in accordance with the EU’s market abuse regulation (MAR). The information was made available publically by the Company’s contact person on October 5th 2018.
Powered by WPeMatico